^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    ACTOnco

    Company:
    Prenetics
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    8ms
    Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma. (PubMed, Clin Transl Immunology)
    Genetic alterations in the p53 pathway may be critical in Asian patients with melanoma undergoing ICI treatment. Further investigation is required to explore this mechanism and validate these findings.
    Checkpoint inhibition • Journal • Tumor mutational burden • IO biomarker • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • MDM2 (E3 ubiquitin protein ligase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    TP53 mutation • KRAS mutation • BRAF mutation • NRAS mutation • KIT mutation • NF1 mutation • TP53 amplification
    |
    ACTOnco
    9ms
    A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial (ESMO 2023)
    Background The phase 3 iPocc trial reported improved progression-free survival (PFS) in OC patients receiving IP over intravenous (IV) carboplatin with IV dose-dense paclitaxel...Low IPRS was also able to predict improved outcomes in appendiceal cancer patients receiving hyperthermic IP therapy with the DNA cross-linking agent mitomycin-c (median PFS: 4.4 vs 1.5 years, p = 0.01). Conclusions The IPRS shows promise in identifying a subset of OC patients likely to benefit from IP platinum treatment. Validation in a larger cohort is warranted.
    P2/3 data • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA wild-type
    |
    ACTOnco
    |
    carboplatin • paclitaxel • mitomycin
    9ms
    The Registry of Genetic Alterations of Taiwan NSCLC by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study - TCOG T1521 Study (IASLC-WCLC 2023)
    In cohort 1, 11.2% (28/251) of the patients had MET amplification, 32.3% (81/251) had been treated with osimertinib, and EGFR C797S was detected in 6.2% (5/81) of these patients... This multi-center registration study is the largest study to investigate comprehensive tissue NGS for specific NSCLC populations in Taiwan. The results provide real-world evidence to support the reimbursement of tissue NGS as a diagnostic test for NSCLC patients.
    Real-world evidence • Clinical • Next-generation sequencing • Real-world
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • ALK positive • MET amplification • RET fusion • MET exon 14 mutation • EGFR C797S • RET mutation • ROS1 fusion • MET mutation • KRAS G12 • EGFR positive • ALK negative
    |
    ACTOnco
    |
    Tagrisso (osimertinib)
    1year
    PIK3CA mutation induces immunogenicity and increases the immune checkpoint inhibitor response in urothelial carcinoma (AACR 2023)
    UC with PIK3CA missense mutation exhibits a higher immunogenicity through enhancing MHC class I and B2M expression. PIK3CA missense mutation is a potential predictive marker for ICI response in UC.
    Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • HLA-A (Major Histocompatibility Complex, Class I, A) • KMT2D (Lysine Methyltransferase 2D) • B2M (Beta-2-microglobulin) • MUC16 (Mucin 16, Cell Surface Associated) • HLA-B (Major Histocompatibility Complex, Class I, B) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • HLA-C (Major Histocompatibility Complex, Class I, C) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    TMB-H • PIK3CA mutation • TMB-L • PIK3CA expression • PIK3CA wild-type
    |
    ACTOnco
    over1year
    Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors (Prenetics Press Release)
    "Prenetics Global Limited...today announced that ACT Genomics, a company which Prenetics recently acquired a majority stake in, has received clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco, the company’s comprehensive genomic profiling test for solid tumors. ACTOnco is intended for use by healthcare professionals to help them inform clinical management decisions in accordance with professional guidelines for cancer patients with solid tumors. This is the first and only Asia-based company to receive FDA clearance for a comprehensive genomic profiling test."
    FDA event
    |
    ACTOnco